Perrigo Plays To OTC Strength With GoodSense Firm Acquisition
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Geiss, Destin & Dunn's GoodSense brand includes more than 1,500 OTC drugs and nutritional products. The deal could help diminish the impact of earnings headwinds on Perrigo's branded consumer health and Rx generic topicals businesses.
You may also be interested in...
Perrigo Hopes Esomeprazole Helps Make Private Label OTCs A Bright Spot
The firm lowers its 2016 guidance as its European branded OTC drug and nutritional product business and its Rx topicals business appear to be major obstacles to escaping its earnings slump.
Another Advertising Review For Goli Nutrition: Church & Dwight Challenges Ashwagandha Claims
NAD review of Goli claims, looking at weight loss, physical performance, sexual function and sales claims, recommended it modify advertising to avoid conveying implied product efficacy claims for Ashwagandha Gummies and modify or discontinue qualified physical performance claim about ingredient KSM-66.
Perrigo Has First US Approval For OTC Omeprazole Mini-Capsule
Capsule is 70% smaller than tablets of omeprazole currently available in Prilosec OTC and generic equivalents, including formulations Perrigo provides for its private label and store brand customers.